• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).第五届欧洲中学教育阶段（ESO）-欧洲肿瘤内科学会（ESMO）晚期乳腺癌国际共识指南（ABC 5）
Ann Oncol. 2020 Dec;31(12):1623-1649. doi: 10.1016/j.annonc.2020.09.010. Epub 2020 Sep 23.
2
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).ESO-ESMO 第 3 版年轻女性乳腺癌国际共识指南（BCY3）。
Breast. 2017 Oct;35:203-217. doi: 10.1016/j.breast.2017.07.017. Epub 2017 Aug 17.
3
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.《第四届欧洲中学教育阶段（ESO）-欧洲肿瘤内科学会（ESMO）晚期乳腺癌国际共识指南（ABC 4）》† 。
Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192.
4
New Zealand experience with implementation of the ESO-ESMO consensus guidelines for advanced breast cancer-report of achievements and lessons learned.新西兰实施 ESO-ESMO 晚期乳腺癌共识指南的经验——成就与教训报告。
Breast. 2022 Jun;63:108-112. doi: 10.1016/j.breast.2022.03.017. Epub 2022 Mar 25.
5
Comparison of 4th ESO-ESMO international consensus guidelines for advance breast cancer and Chinese anti-cancer association committee of Breast Cancer Society guideline.第 4 版 ESO-ESMO 国际晚期乳腺癌共识指南与中国抗癌协会乳腺癌专业委员会指南比较。
Breast. 2019 Jun;45:36-42. doi: 10.1016/j.breast.2019.02.009. Epub 2019 Feb 22.
6
ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4).ESO-ESMO 4 版年轻女性乳腺癌国际共识指南（BCY4）。
Ann Oncol. 2020 Jun;31(6):674-696. doi: 10.1016/j.annonc.2020.03.284. Epub 2020 Mar 19.
7
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).第三届欧洲中学教育阶段（ESO）-欧洲肿瘤内科学会（ESMO）晚期乳腺癌国际共识指南（ABC 3）
Ann Oncol. 2017 Jan 1;28(1):16-33. doi: 10.1093/annonc/mdw544.
8
ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5).ESO-ESMO 第五次国际年轻女性乳腺癌共识指南（BCY5）。
Ann Oncol. 2022 Nov;33(11):1097-1118. doi: 10.1016/j.annonc.2022.07.007. Epub 2022 Aug 4.
9
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).第三届欧洲中学教育阶段（ESO）-欧洲肿瘤内科学会（ESMO）晚期乳腺癌国际共识指南（ABC 3）
Breast. 2017 Feb;31:244-259. doi: 10.1016/j.breast.2016.10.001. Epub 2016 Dec 5.
10
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.欧洲肿瘤内科学会（ESO）-欧洲医学肿瘤学会（ESMO）晚期乳腺癌第二版国际共识指南（ABC2）†
Ann Oncol. 2014 Oct;25(10):1871-1888. doi: 10.1093/annonc/mdu385. Epub 2014 Sep 18.

引用本文的文献

1
The efficacy of trastuzumab deruxtecan in Chinese breast cancer patients: a real-world multicenter study.曲妥珠单抗德鲁昔康在中国乳腺癌患者中的疗效：一项真实世界多中心研究。
Front Oncol. 2025 Aug 18;15:1582498. doi: 10.3389/fonc.2025.1582498. eCollection 2025.
2
Beyond the Microscope: Integrating Liquid Biopsies into the Molecular Pathology Era of Endometrial Cancer.超越显微镜：将液体活检纳入子宫内膜癌分子病理学时代
Int J Mol Sci. 2025 Aug 19;26(16):7987. doi: 10.3390/ijms26167987.
3
Risk prediction models for depression in cancer survivors: A systematic review and meta-analysis.癌症幸存者抑郁症风险预测模型：系统评价与荟萃分析。
Medicine (Baltimore). 2025 Aug 22;104(34):e43978. doi: 10.1097/MD.0000000000043978.
4
Integrated computational and preclinical evaluation of novel synthetic pyrazole pyrazoline thiazole derivative for breast cancer therapeutics.新型合成吡唑并吡唑啉噻唑衍生物用于乳腺癌治疗的综合计算和临床前评估
Sci Rep. 2025 Aug 26;15(1):31412. doi: 10.1038/s41598-024-83046-7.
5
Validation of a Quantitative Ultrasound Texture Analysis Model for Early Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: A Prospective Serial Imaging Study.用于早期预测乳腺癌新辅助化疗反应的定量超声纹理分析模型的验证：一项前瞻性系列成像研究
Cancers (Basel). 2025 Aug 7;17(15):2594. doi: 10.3390/cancers17152594.
6
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis.哌柏西利联合内分泌治疗在激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌中的真实世界研究与随机对照研究的疗效比较：系统评价与荟萃分析
JNCI Cancer Spectr. 2025 Sep 1;9(5). doi: 10.1093/jncics/pkaf083.
7
Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study.曲美木单抗联合度伐利尤单抗与节拍口服长春瑞滨联合使用：II期MOVIE研究乳腺癌队列的结果。
Breast. 2025 Aug 5;83:104549. doi: 10.1016/j.breast.2025.104549.
8
Breast cancer with gastric metastasis in invasive lobular carcinoma: a case report and literature review.浸润性小叶癌伴胃转移的乳腺癌：一例报告及文献复习
Front Oncol. 2025 Jul 24;15:1596207. doi: 10.3389/fonc.2025.1596207. eCollection 2025.
9
Long-term survival outcomes and subtype variations between primary breast cancer and liver metastases in 542 patients with advanced breast cancer: insights from a real-world analysis.542例晚期乳腺癌患者原发性乳腺癌与肝转移的长期生存结果及亚型差异：一项真实世界分析的见解
Discov Oncol. 2025 Aug 7;16(1):1493. doi: 10.1007/s12672-025-03342-0.
10
Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe.欧洲HR+/HER2-晚期乳腺癌患者一线哌柏西利与芳香化酶抑制剂治疗的真实世界临床结局
Breast Cancer Res Treat. 2025 Aug 6. doi: 10.1007/s10549-025-07707-5.

本文引用的文献

1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌（KEYNOTE-355）：一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
2
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.TBCRC 048：奥拉帕利治疗转移性乳腺癌及同源重组相关基因变异的 II 期研究。
J Clin Oncol. 2020 Dec 20;38(36):4274-4282. doi: 10.1200/JCO.20.02151. Epub 2020 Oct 29.
3
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.他拉唑帕尼与化疗治疗胚系BRCA1/2突变的HER2阴性晚期乳腺癌患者：EMBRACA试验的最终总生存结果
Ann Oncol. 2020 Nov;31(11):1526-1535. doi: 10.1016/j.annonc.2020.08.2098. Epub 2020 Aug 20.
4
Bone health in cancer: ESMO Clinical Practice Guidelines.癌症中的骨骼健康：ESMO临床实践指南
Ann Oncol. 2020 Dec;31(12):1650-1663. doi: 10.1016/j.annonc.2020.07.019. Epub 2020 Aug 12.
5
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.在 HER2CLIMB 试验中，曲妥珠单抗联合卡培他滨治疗既往治疗的 HER2 阳性乳腺癌伴脑转移的颅内疗效和生存。
J Clin Oncol. 2020 Aug 10;38(23):2610-2619. doi: 10.1200/JCO.20.00775. Epub 2020 May 29.
6
Communication about Sexual Health in Breast Cancer: What Can We Learn from Patients' Self-Report and Clinic Dialogue?乳腺癌患者的性健康沟通：从患者自我报告和临床对话中我们能学到什么？
Patient Educ Couns. 2020 Sep;103(9):1821-1829. doi: 10.1016/j.pec.2020.03.029. Epub 2020 Apr 4.
7
Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603).奥昔布宁与安慰剂治疗有或无乳腺癌女性潮热的随机双盲临床试验（ACCRU SC - 1603）
JNCI Cancer Spectr. 2019 Oct 21;4(1):pkz088. doi: 10.1093/jncics/pkz088. eCollection 2020 Feb.
8
Cannabis sativa: Much more beyond Δ-tetrahydrocannabinol.大麻：远不止 Δ-四氢大麻酚。
Pharmacol Res. 2020 Jul;157:104822. doi: 10.1016/j.phrs.2020.104822. Epub 2020 Apr 23.
9
Patient-Reported Barriers and Facilitators to Seeking and Accessing Support in Gynecologic and Breast Cancer Survivors With Sexual Problems: A Systematic Review of Qualitative and Quantitative Studies.妇科和乳腺癌幸存者中存在性问题时寻求和获得支持的障碍和促进因素：定性和定量研究的系统评价。
J Sex Med. 2020 Jul;17(7):1326-1358. doi: 10.1016/j.jsxm.2020.03.004. Epub 2020 Apr 21.
10
Laser-Based Devices for Female Genitourinary Indications: Position Statements From the European Society for Sexual Medicine (ESSM).基于激光的女性泌尿生殖系统适应证治疗设备：欧洲性医学学会（ESSM）立场声明。
J Sex Med. 2020 May;17(5):841-848. doi: 10.1016/j.jsxm.2020.02.013. Epub 2020 Mar 20.

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).

作者信息

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro M S, André F, Barrios C H, Bergh J, Bhattacharyya G S, Biganzoli L, Boyle F, Cardoso M-J, Carey L A, Cortés J, El Saghir N S, Elzayat M, Eniu A, Fallowfield L, Francis P A, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely B E, Kim S-B, Lin N U, Mertz S A, Neciosup S, Offersen B V, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo H S, Sledge G W, Thomssen C, Vorobiof D A, Wiseman T, Xu B, Norton L, Costa A, Winer E P

机构信息

Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.

Sharett Division of Oncology, Hadassah University Hospital, Jerusalem, Israel.

出版信息

Ann Oncol. 2020 Dec;31(12):1623-1649. doi: 10.1016/j.annonc.2020.09.010. Epub 2020 Sep 23.

DOI:10.1016/j.annonc.2020.09.010
PMID:32979513
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7510449/
Abstract
摘要